EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy

Yi-Chen Zhang, Zi-Qin Ding, Shi-Yao Xu iD, Ji-Yu Chen, Ming-Hui Chen, Bing-Qing Luo, Ying Wang iD, Yan-Yi Wu, Xin-Yao Lv, Xing-Zhu Liu, Chen Zhao, Qing-Huai Liu und 1 weitere

Proceedings of the National Academy of Sciences · 25.08.2026 · 123 (34)

DOI: 10.1073/pnas.2602779123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 21.08.2026. Verfasst von Yi-Chen Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase, Endothelial Cells, Retinal Neovascularization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), "333 Project" of Jiangsu Province ("333" Project of Jiangsu Province), Jiangsu Province Hospital High-level Talent Cultivation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic microvasculopathy is a serious diabetes complication, with diabetic retinopathy (DR) being a leading cause of blindness worldwide due to immature, leaky neovessels. Antiangiogenic therapies merely suppress neovascularization, leaving the retina oxygen-starved and prone to regrowth. Thus, therapies that stabilize aberrant neovessels are needed. We identify the RNA demethylase ALKBH3 as an epitranscriptional driver of diabetic microvasculopathy. Upregulated ALKBH3 in diabetic vascular endothelial cells promoted a pathological shift to an unstable, pro-angiogenic phenotype, disrupting blood-retinal barrier and forming immature neovessels, which impaired vision. Conversely, removing ALKBH3 protected against this. Mechanistically, ALKBH3 demethylated BMP2 mRNA to increase its stability via YTHDF2. We further developed a neovasculature-targeting nanoparticle delivering the ALKBH3 inhibitor HUHS015, which normalized retinal neovascularization by simultaneously limiting growth and promoting maturation. It acted synergistically with vascular endothelial growth factor (VEGF) blockade, suggesting potential for anti-VEGF-resistant cases. Our work defines ALKBH3 as a key mediator of diabetic microvasculopathy and supports a VEGF-independent therapeutic paradigm that shifts the focus from vessel suppression to active normalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyAlkB Homolog 3, Alpha-Ketoglutarate-Dependent DioxygenaseEndothelial CellsRetinal NeovascularizationNeovascularization, PathologicHumansAnimalsVascular Endothelial Growth Factor ARNA-Binding ProteinsNerve Tissue ProteinsMiceBlood-Retinal BarrierEpitranscriptome

Stichwörter der Autor:innen

ALKBH3N1-methyladenosinediabetic retinopathyendothelial cell

Substanzen

AlkB Homolog 3, Alpha-Ketoglutarate-Dependent DioxygenaseALKBH3 protein, humanYTHDF2 protein, humanVascular Endothelial Growth Factor ARNA-Binding ProteinsNerve Tissue Proteins

Autor:innen und Institutionen

  • Department of Ophthalmology, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029, China.
  • Key Laboratory for Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
  • Eye Institute and Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital, Fudan University, Shanghai 200031, China.

ORCID-Profile: Shi-Yao Xu, Ying Wang, Xue Chen

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • "333 Project" of Jiangsu Province ("333" Project of Jiangsu Province)
  • Jiangsu Province Hospital High-level Talent Cultivation Program
  • “333 Project” of Jiangsu Province

Zitieren

APA

Zhang, Y. C., Ding, Z. Q., Xu, S. Y., Chen, J. Y., Chen, M. H., Luo, B. Q., Wang, Y., Wu, Y. Y., Lv, X. Y., Liu, X. Z., Zhao, C., Liu, Q. H., & Chen, X. (2026). ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy. Proceedings of the National Academy of Sciences, 123(34). https://doi.org/10.1073/pnas.2602779123

Vancouver

Zhang YC, Ding ZQ, Xu SY, Chen JY, Chen MH, Luo BQ, et al. ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy. Proceedings of the National Academy of Sciences. 2026;123(34). doi:10.1073/pnas.2602779123

BibTeX
@article{Zhang2026,
  author = {Zhang, Yi-Chen and Ding, Zi-Qin and Xu, Shi-Yao and Chen, Ji-Yu and Chen, Ming-Hui and Luo, Bing-Qing and Wang, Ying and Wu, Yan-Yi and Lv, Xin-Yao and Liu, Xing-Zhu and Zhao, Chen and Liu, Qing-Huai and Chen, Xue},
  title = {ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {34},
  doi = {10.1073/pnas.2602779123}
}
Kostenlos starten →